A First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability and Pharmacokinetics of LML134 in Healthy Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 133
- 试验地点
- 1
- 主要终点
- Cardiovascular safety assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion
研究概览
简要总结
Phase I study to assess the safety, tolerability and pharmacokinetics of ascending single and multiple doses of the investigational medicinal product in healthy volunteers
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female subjects age 18 to 55 years of age included, and in good health as determined by medical history, physical examination, vital signs, electrocardiogram, and laboratory tests.
- •Written informed consent must be obtained before any assessment is performed.
- •Able to communicate well with the Investigator, to understand and comply with the requirements of the study.
排除标准
- •History or presence of epilepsy or of seizures or convulsions of any kind.
- •Any clinically relevant abnormalities identified in the resting EEG during screening, or pre-ictal signs or other clinically relevant abnormalities in the hyperventilation or intermittent photic stimulation EEG during screening.
- •History of head trauma leading to clinically significant symptoms in the past two years.
- •Applies only to subjects enrolled in Part 2 MAD. Score "yes" on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or "yes" on any item of the Suicidal Behavior section, except for the "Non-Suicidal Self-Injurious Behavior" (item also included in the Suicidal Behavior section), if this behavior occurred in the past 2 years.
- •Significant illness including any clinically significant infectious disease which has not resolved within two (2) weeks prior to initial dosing.
- •History or presence of significant hematological abnormalities or immunodeficiency or any condition that might compromise the immune system (infection, vaccination), of any etiology as indicated by clinically significantly abnormal values of any of the following hematologic parameters: thrombocyte, RBC count, total WBC count and differentials presented as % of total white blood cell count and as absolute concentrations.
- •History or presence of any thyroid disease as indicated by any clinically relevant abnormality on thyroid stimulating hormone test (TSH).
- •History or presence of any chronic eye disease other than refractive error, strabismic amblyopia, or anisometropic amblyopia.
- •Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant.
研究组 & 干预措施
Single dose study part
there will be 8 cohorts of healthy volunteers dosed with single doses of LML134 (8 planned dose levels) or with placebo and 2 potential additional cohorts (also dosed with single dose of LML134 or placebo)
干预措施: LML134 (Drug)
Single dose study part
there will be 8 cohorts of healthy volunteers dosed with single doses of LML134 (8 planned dose levels) or with placebo and 2 potential additional cohorts (also dosed with single dose of LML134 or placebo)
干预措施: Placebo (Drug)
Multiple dose study part
there will be 3 cohorts of healthy volunteers dosed with multiple doses of LML134 (3 planned dose levels) or placebo and one potential additional cohort (also dosed with multiple doses of LML134 or placebo)
干预措施: LML134 (Drug)
Multiple dose study part
there will be 3 cohorts of healthy volunteers dosed with multiple doses of LML134 (3 planned dose levels) or placebo and one potential additional cohort (also dosed with multiple doses of LML134 or placebo)
干预措施: Placebo (Drug)
结局指标
主要结局
Cardiovascular safety assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion
时间窗: Starting about 24 hours before dosing and continued until about 7-14 days after last dose
This safety outcome combines the measure of a set of cardiovascular safety parameters extracted from ECGs, 25 hours-Holter ECGs and from vital signs assessments
Ocular safety assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion
时间窗: Starting about 24 hours before dosing and continued until about 7-14 days after last dose
This safety outcome combined the measure of a set of ocular parameters including best corrected visual acuity and other parameters assessed by the mean of slit lamp biomicroscopy and dilated ophthalmoscopy examinations and by optical coherence tomography and electroretinography
Central nervous system safety assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion
时间窗: Starting about 24 hours before dosing and continued until about 7-14 days after last dose
This safety outcome combines the measure of a set of central nervous system safety parameters extracted from EEGs and neurological examinations
General safety assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion
时间窗: Starting about 24 hours before dosing and continued until about 7-14 days after last dose
This general safety outcome combines the measure of blood laboratory parameters and the outcome of physical examinations
Adverse events assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion
时间窗: Starting about 24 hours before dosing and continued until about 7-14 days after last dose
This safety outcome combines the measure of the number of subjects experiencing adverse events (AEs), the nature and severity of those AEs and their relationship to the study treatments.
次要结局
- PK of LML134: Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) in Part 1 and Part 3(Starting 1hour prior to dosing on Day 1 and until 72 hours after dosing (Day 4))
- Pharmacokinetics (PK) of LML134: time to reach the maximum concentration after a single drug administration (Tmax) in Part 1 and in Part 3(Starting 1hour prior to dosing on Day 1 and until 72 hours after dosing (Day 4))
- PK of LML134: Observed maximum serum concentration following single drug administration (Cmax) in Part 1 and Part 3(Starting 1hour prior to dosing on Day 1 and until 72 hours after dosing (Day 4))
- PK of LML134: The area under the serum concentration-time curve from time zero to the end of the dosing interval tau at steady state (AUCtau,ss) in Part 2(Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17))
- PK of LML134: The effective half-life based on drug accumulation at steady state (T1/2,acc) in Part 2(Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17))
- PK of LML134: The accumulation ratio (Racc) in Part 2(Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17))
- PK of LML134: time to reach the maximum concentration after the first drug administration (Tmax) in Part 2(Starting 1hour prior the first dose administration (Day 1) until 24hr after the first dose administration on Day 2)
- PK of LML134: The average steady state serum concentration during multiple dosing (Cav,ss) in Part 2(Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17))
- PK of LML134: time to reach the maximum concentration after the last drug administration (Tmax) in Part 2(Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17))
- PK of LML134: Observed maximum serum concentration following the first drug administration (Cmax) in Part 2(Starting 1hour prior the first dose administration (Day 1) until 24hr after the first dose administration on Day 2)
- PK of LML134: Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) after the first dose administration in Part 2(Starting 1hour prior the first dose administration (Day 1) until 24hr after the first dose administration on Day 2)
- PK of LML134: Observed maximum serum concentration following drug administration at steady state (Cmax,ss) in Part 2(Starting 1hour prior the first dose administration (Day 1) until 48hour after the last dose administration (Day 17))